Raymond James Financial Services Advisors, Inc. Puma Biotechnology, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 21, 2020	SELL	$6.28 - $14.57 $62,988 - $146,137	-10,030 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$6.5 - $10.73 $403 - $665	-62 Reduced 0.61%	10,030 $88,000
Q3 2019 Nov 07, 2019	BUY	$8.75 - $12.85 $88,305 - $129,682	10,092 New	10,092 $109,000

Others Institutions Holding PBYI

# of Institutions

102

Shares Held

29.1M

Call Options Held

60.6K

Put Options Held

16.3K

Vanguard Group Inc Valley Forge, PA

3.64M
Shares

$10.5 Million
0.0% of portfolio
Black Rock Inc. New York, NY

3.57M
Shares

$10.4 Million
0.0% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

3.06M
Shares

$8.88 Million
0.42% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.88M
Shares

$8.35 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

1.97M
Shares

$5.71 Million
0.02% of portfolio

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $132M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account